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The ESPAC-1, ESPAC-1 plus, and early ESPAC-3(v1) results (458 randomized patients; 364 deaths) were used to estimate the
effectiveness of adjuvant 5FU/FA vs resection alone for pancreatic cancer using meta-analysis. The pooled hazard ratio of 0.70 (95%
CI¼0.55–0.88) P¼0.003, and the median survival of 23.2 (95% CI¼20.1–26.5) months with 5FU/FA vs 16.8 (95% CI¼14.3–
19.2) months with resection alone supports the use of adjuvant 5FU/FA in pancreatic cancer.
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The results of two recent randomized controlled trials of adjuvant
treatment in pancreatic cancer (Oettle et al, 2007; Regine et al,
2008) have further raised the interest regarding optimum therapy
in this disease. The CONK-001 trial showed that postoperative
gemcitabine significantly delayed the development of recurrent
disease compared with observation alone (Oettle et al, 2007) and
subsequent analysis showed improved overall median survival
(Neuhaus et al, 2008). The Radiation Therapy Oncology Group
Study (RTOG) 9704 trial showed no difference in the overall
survival between two chemoradiotherapy regimens, although
in a subgroup analysis showed that the addition of gemcitabine
(rather than 5FU) to postoperative adjuvant 5FU-based chemo-
radiotherapy significantly improved the survival in those patients
with cancer in the head of the pancreas (Regine et al, 2008).
The European Study Group for Pancreatic Cancer (ESPAC)
recruited 550 patients into the ESPAC-1 adjuvant trial (Figure 1) of
which 289 patients were in a 2 2 factorial design, powered
to investigate the roles of adjuvant chemotherapy (5FU with
folinic acid (FA)) and chemoradiotherapy on overall survival
(Neoptolemos et al, 2001, 2004). The final results confirmed that
only adjuvant chemotherapy provided a significant survival benefit
(Neoptolemos et al, 2004). The trial, however, was not powered for
a direct comparison between the 5FU/FA and surgery alone
subgroups of the 2 2 design. Of the 550 patients in ESPAC-1, 192
patients were entered into a direct randomised comparison
between 5FU/FA and observation alone with clinician’s choice of
background chemoradiotherapy if indicated. This randomised
comparison is referred to as the ESPAC-1 plus trial and was
conducted as part of the ESPAC-1 adjuvant trial based on identical
eligibility criteria and treatment schedules. Patients were recruited
in parallel and in addition to the recruitment target and as such
were always intended to be additional evidence not powered for
analysis in isolation. The ESPAC-3(v1) trial was initially a three
arm study of adjuvant 5FU/FA vs gemcitabine vs observation.
Following the publication of the final results of ESPAC-1
(Neoptolemos et al, 2004), the Independent Data Monitoring
Committee advised that the observation arm be dropped from
ESPAC-3(v2). The Independent Data Monitoring Committee also
recommended reporting of the combined results of 5FU/FA vs
observation from both trials as this was planned as part of the
original protocol of ESPAC-3(v1). In the 2 2 component of
ESPAC-1 (Figure 1), patients randomised to chemotherapy (either
chemotherapy alone or with chemoradiotherapy) were compared
with the patients randomised not to receive chemotherapy (either
surgery alone or with chemoradiotherapy) as per the 2 2 design,
but the unexpected somewhat negative effect of chemoradio-
therapy may have affected the result. Hence these data comparing
the adjuvant chemotherapy alone vs surgery alone subgroups of
the 2 2 design are important as a trial including a surgery alone
arm is now unlikely to be repeated. The results are thus unique
offering for the first time an unbiased randomised comparison of
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sadjuvant 5FU/FA vs observation following the resection of
pancreatic ductal adenocarcinoma. In addition, the use of meta-
analysis to combine individual patient data across the three studies
increases the overall sample size which, in turn, increases the
statistical power of the analysis.
METHODS
The inclusion criteria in ESPAC-1, ESPAC-1 plus, and ESPAC-
3(v1) were identical and postoperative restaging and CA 19.9
values were not used to determine patient inclusion in these
studies (Neoptolemos et al, 2001, 2004; www.cancernorth.nhs.uk/
portal_repository/files/trial_sum_espac.pdf). Similarly, the che-
motherapy regimen used was identical in all three studies
comprising an intravenous bolus of leucovorin (folinic acid;
20mgm
 2), followed by an intravenous bolus of 5FU (425mgm
 2)
on each of 5 consecutive days every 28 days for six cycles. There
were 144 patients from the two groups of the ESPAC-1 2 2 design
(69 observation, 75 5FU/FA) with a median follow-up of the 24
alive patients of 78 (interquartile range¼45–92) months (Table
1). The ESPAC-1 plus component recruited 192 patients (95
observation, 19 (20%) of whom received background chemor-
adiotherapy; 97 5FU/FA, 25 (26%) of whom received background
chemoradiotherapy) with a median follow-up of the 40 alive
patients of 64 (interquartile range¼20–89) months. There were
122 patients in ESPAC-3(v1) at closure of the observation arm in
this trial (61 observation, 61 5FU/FA) with a median follow-up of
the 30 alive patients of 54 (interquartile range¼34–60) months.
These data provide a direct randomised comparison of 5FU/FA vs
observation alone based on the intention-to-treat principle. For the
outcome of overall survival, a random effects model was used to
combine the trial level hazard ratios (HRs), estimated from the
individual patient data, using an inverse variance meta-analysis.
Survival estimates are presented as simple, non-stratified Kaplan–
Meier curves across all trials. The overall estimate of the treatment
effect is adjusted by any influence of trial.
RESULTS
The eligibility criteria across trials were similar, and as such the
patient and tumour characteristics (Table 1) were comparable with
treatment schedules also identical across trials. At the time of
analysis, there were 120 (83.3%) deaths in ESPAC-1, 152 (79.2%)
deaths in ESPAC-1 plus, and 92 (75.4%) deaths in ESPAC-3(v1)
(Table 2). The heterogeneity between trials was non-significant,
and pooling the data is considered justifiable (Figures 2 and 3).
The overall survival (Figure 4) was superior in patients rando-
mized to 5FU/FA compared to those randomized to observation
(pooled HR¼0.70 (95% CI¼0.55–0.88); P¼0.003 (Table 2)) with
evidence of low statistical heterogeneity (P¼0.27, I
2¼25%,
Figure 3). The pooled effect of chemotherapy is estimated to
reduce the risk of death by 30% compared to surgery alone.
Combined overall median survival (obtained from simple Kaplan–
Meier curves non-stratified by trial) was 23.2 (95% CI¼20.1–26.5)
550 patients with histologically proven adenocarcinoma of 
the pancreas having undergone potentially curative resection 
ESPAC-1
2×2 randomisation
289 (53%)
OBS
N=69
CRT
N=73
CT
N=75
CRT+CT
N=72
ESPAC-1 plus
CRT only randomisation
69 (12%) 
ESPAC-1 plus
CT only randomisation
192 (35%) 
Obs.
N=95
CT
N=97
Obs.
N=36
CRT
N=33
Figure 1 ESPAC-1 trial design.
Table 1 Patient characteristics and observation of patients randomised to 5FU/FA
ESPAC-1 (N¼144) ESPAC-1 plus (N¼192) ESPAC-3 (N¼122)
Total
Obs. (N¼69) 5FU/FA (N¼75) Obs. (N¼95) 5FU/FA (N¼97) Obs. (N¼61) 5FU/FA (N¼61) N¼458
Sex:
Male 47 (68%) 44 (59%) 54 (57%) 60 (62%) 40 (66%) 34 (56%) 279 (61%)
Female 22 (32%) 31 (41%) 41 (43%) 37 (38%) 21 (34%) 27 (44%) 179 (39%)
Age:
Median (years) 60 61 60 57 62 61 60
IQR 55–65 55–67 54–69 51–63 53–69 55–67 54–67
Range 36–84 41–83 32–84 28–78 33–77 42–80 28–84
Max. tumour size:
Median (cm) 3.0 3.0 3.0 3.0 2.9 2.8 3.0
IQR 2.0–3.5 2.5–4.0 2.3–3.5 2.1–4.0 2.0–3.5 2.0–3.3 2.2–3.5
Range 0.6–5.0 0.6–8.0 0.5–9.0 0.6–10.0 1.0–6.0 0.3–6.0 0.3–10.0
Grade:
Well 12 (18%) 21 (31%) 19 (20%) 18 (20%) 5 (8%) 11 (18%) 86 (20%)
Moderate 40 (62%) 28 (42%) 52 (56%) 57 (62%) 43 (70%) 30 (50%) 250 (57%)
Poor 13 (20%) 18 (27%) 22 (24%) 17 (18%) 12 (20%) 18 (30%) 100 (23%)
Undifferentiated 0 0 0 0 1 (2%) 1 (2%) 2 (0%)
Lymph nodes:
Neg. 25 (37%) 35 (49%) 51 (56%) 48 (52%) 21 (34%) 18 (30%) 198 (45%)
Pos. 42 (63%) 36 (51%) 40 (44%) 45 (48%) 40 (66%) 42 (70%) 245 (55%)
Resection margins:
Neg. 60 (87%) 61 (81%) 73 (77%) 74 (76%) 38 (62%) 37 (61%) 343 (75%)
Pos. 9 (13%) 14 (19%) 22 (23%) 23 (24%) 23 (38%) 24 (39%) 115 (25%)
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months for observation with 2- and 5-year survival estimates of
49%, 24% for 5FU/FA and 37%, 14% for observation (Figures 4 and
5, Table 2). A sensitivity analysis excluding the ESPAC-1 plus study
estimated that chemotherapy reduced the risk of death by 23%
compared to surgery alone (HR¼0.77, 95%CI¼0.59, 1.01).
DISCUSSION
This individual patient data meta-analysis of ESPAC-1, ESPAC-1
plus and ESPAC-3 trials showed significantly better overall
survival for patients randomized to 5FU/FA with an HR of 0.70
(95% CI¼0.55, 0.88; P¼0.003) indicating a significant reduction
in the risk of death of 30% with 5FU/FA compared with surgery
alone.
The CONKO-001 trial (Oettle et al, 2007) found a significantly
improved median disease-free survival in favour of gemcitabine
(13.4 (range¼11.4–15.3) months) compared to observation (6.9
(range¼6.1–7.8) months; Po0.001). The overall median survival
was 22.1 (range¼18.4–25.8) months for the gemcitabine group,
and 20.2 (range¼17–23.4) months for the surgery alone group
(HR¼0.79 (95% CI¼0.62–1.01); P¼0.06). The primary end
point was disease-free survival, whereas a confounding factor for
overall survival was the fact that a large proportion of the control
group received gemcitabine on relapse. The CONKO-001 investi-
gators concluded that chemotherapy with gemcitabine offered the
best benefit/risk ratio of all currently available adjuvant treatment
options (Oettle et al, 2007). Comparison with the current study
using an adjusted indirect comparison, which maintains the within
trial randomisation (Bucher et al, 1997) shows that the adjuvant
5FU/FA has at least similar survival results to those of gemcitabine
(adjusted indirect HR of 0.89 (95% CI¼0.63–1.25) for 5FU
compared with gemcitabine), although equivalence cannot be
claimed due to the wide confidence interval and should be
interpreted cautiously as not as reliable as a direct comparison.
Furthermore, the toxicity for gemcitabine in the CONKO-001 trial
appears less than that for 5FU/FA (Neoptolemos et al, 2001, 2004),
but a robust assessment of the benefit/risk ratio can only be
properly addressed by a concurrently randomised comparison as
will be carried out in ESPAC-3.
The RTOG-9704 trial compared pre and postchemo-
radiation gemcitabine (1000mgm
 2day
 1) to pre and postche-
moradiation 5FU (250mgm
 2day
 1 given as a continuous
infusion) in patients who had undergone pancreatic resection
(Regine et al, 2008). Both arms of the study received 5FU-based
chemoradiotherapy (50.4Gy), with the chemotherapy given for 3
weeks pre- and 12 weeks postchemoradiotherapy (Regine et al,
2008). Analysis was restricted to 442 ‘eligible’ patients out of the
total of 538 patients originally recruited. There was no difference in
the overall survival between the two arms, but a prospectively
powered subgroup analysis of the 380 patients with pancreas
head cancer revealed a reduction in the risk of death for patients
in the gemcitabine-based chemoradiation arm (HR¼0.79; 95%
CI¼0.63–0.99; P¼0.047). The conclusions of the ESPAC-1 trial
and subsequent meta-analyses with other adjuvant trials suggest
that there is no good clinical evidence for the use of chemoradia-
tion in pancreatic cancer in the adjuvant setting (Neoptolemos
et al, 2001, 2004; Stocken et al, 2005) or in patients with locally
advanced disease (Yip et al, 2006; Sultana et al, 2007a,b), and more
recent results are conflicting (Chauffert et al, 2008; Loehrer et al,
2008). The apparent failure of chemoradiation in pancreatic
Table 2 Survival estimates
Comparison
Number of
patients
Number of
deaths
Median survival
in months (95% CI)
Survival rates
at 1, 2, and 5 years
Hazard ratio
(95% CI)
ESPAC-1 144 120 18.6 (15.7, 23.6) 67%, 42%, 18% 1.0
ESPAC-1 plus 192 152 17.4 (15.8, 21.7) 66%, 38%, 19% 1.03 (0.81, 1.32)
a
ESPAC-3 122 92 24.3 (19.8, 30.9) 80%, 51%, 20% 0.86 (0.66, 1.11)
a
Overall 458 364 19.6 (17.3, 22.0) 70%, 43%, 19% —
ESPAC-1
Obs 69 63 16.9 (12.3, 24.8) 64%, 39%, 10% 1.0
5FU/FA 75 57 21.7 (14.8, 27.3) 70%, 44%, 27% 0.70 (0.49, 1.01)
ESPAC-1 plus
Obs. 95 80 12.8 (10.2, 16.9) 52%, 28%, 14% 1.0
5FU/FA 97 72 24.0 (18.8, 29.4) 81%, 49%, 24% 0.58 (0.42, 0.80)
ESPAC-3
Obs. 61 47 20.3 (18.1, 31.7) 79%, 48%, 20% 1.0
5FU/FA 61 45 25.9 (18.3, 36.3) 82%, 54%, 20% 0.89 (0.59, 1.33)
Overall
Obs. 225 190 16.8 (14.3, 19.2) 63%, 37%, 14% —
5FU/FA 233 174 23.2 (20.1, 26.5) 77%, 49%, 24% 0.70 (0.55, 0.88)
b
aPLR¼0.33.
bAdjusted by trial. Bold value signifies P¼0.003.
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Figure 2 Kaplan–Meier survival curves stratified by trial.
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scancer may be ascribed to interference of systemic chemo-
therapy scheduling and/or significant biological effects, such as
the prometastasizing effects of ionising radiation (Biswas et al,
2007).
In conclusion, the current evidence supports the continued use
of adjuvant 5FU/FA for treating pancreatic cancer. The results of
the ESPAC-3(v2) trial will determine whether gemcitabine is
superior or not to this treatment.
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